Hypothesis\nEndogenous retroviral elements (ERVs) set the length of the safe window during OSK‑mediated partial reprogramming by regulating chromatin accessibility and innate immune activation.\n\n## Mechanistic Basis\n- OSK expression opens chromatin at pluripotency promoters, but simultaneous derepression of ERVs can trigger cGAS‑STING sensing of cytosolic nucleic acids, leading to interferon‑driven senescence or apoptosis.\n- Tissues with low basal ERV expression (e.g., retinal pigment epithelium) experience delayed ERV activation, extending the window where epigenetic age declines without loss of lineage markers.\n- Conversely, high ERV activity in tissues such as liver or brain accelerates innate immune signaling, shortening the safe window and increasing risk of identity loss.\n- This view integrates the observation that chemical cocktails can reverse hallmarks without genetic manipulation, as they may modulate ERV‑associated chromatin states without provoking immune sensing.\n\n## Testable Predictions\n1. Single‑cell ERV transcript levels will inversely correlate with the duration of OSK exposure required to achieve maximal epigenetic age reduction in a given tissue.\n2. Knockdown of the ERV silencing factor TRIM28 will shorten the safe window, causing earlier loss of fibroblast markers (VIM, COL1A1) despite continued epigenetic rejuvenation.\n3. Overexpression of a dominant‑negative cGAS will lengthen the safe window, allowing prolonged OSK expression without somatic identity loss in murine liver.\n4. Combining OSK AAV with a STING inhibitor will produce greater epigenetic rejuvenation and better functional outcomes than OSK alone in aged mouse models.\n\n## Experimental Design\n- Step 1: Generate a panel of primary mouse cell types (fibroblasts, hepatocytes, retinal pigment epithelium, neurons) and measure baseline ERV expression (single‑cell RNA‑seq) and cGAS levels.\n- Step 2: Transduce each cell type with a doxycycline‑inducible OSK construct; treat with varying doxycycline pulses (6 h, 12 h, 24 h, 48 h) and collect samples at 0, 3, 6, 12, 24 d.\n - Quantify epigenetic age (Horvat clock), lineage‑specific markers (immunofluorescence/flow), and ERV/cGAS‑STING pathway activation (phospho‑STING, IFN‑β).\n- Step 3: In parallel, perturb ERV regulation: siRNA against TRIM28 or CRISPRa of a specific ERV locus; repeat OSK pulses and assess shifts in the safe window.\n- Step 4: In vivo, administer OSK‑AAV to aged mice with or without a STING inhibitor (e.g., H‑151); monitor cardiac and hepatic epigenetic age, fibrosis scores, and signs of dedifferentiation (alpha‑fetoprotein, Sox9) over 8 weeks.\n- Step 5: Perform single‑cell multi‑omics to correlate ERV chromatin accessibility (ATAC‑seq) with transcriptional trajectories and determine the point at which identity genes are downregulated.\n\n## Potential Impact\nIf validated, this hypothesis would provide a biomarker‑driven strategy to personalize OSK dosing based on tissue‑specific ERV/innate immune profiles, improving safety and efficacy of partial reprogramming therapies.\n\n## References\n- OSK AAV extends lifespan and reduces epigenetic age in heart and liver of aged mice without teratomas liebertpub\n- Chemical cocktails reverse aging hallmarks across epigenome, transcriptome, metabolome aging-us\n- Epigenetic age drops linearly days 3‑15 while fibroblast markers remain high acel\n- First human clinical trial of OSK gene therapy cleared for age‑related vision diseases lifespan\n- Dual AAV inducible OSKM shows limited brain transduction due to poor co‑transduction and DOX penetration liebertpub\n- Next‑generation neurotropic AAV variants cross blood‑brain barrier science